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Purpose: Radiation-induced lymphopenia (RIL) is the result of direct toxicity to circulating
lymphocytes as they traverse the irradiated field, occurs in 40% to 70% of patients who undergo
conventional external beam radiation therapy, and is associated with worse outcomes in multiple solid
tumors. As immunotherapy strategies evolve, a better understanding of radiation’s effects on the
immune system is needed in order to develop rational methods of combining RT with immunotherapy.
Methods and materials: This paper is a review of the available literature on the clinical significance
and dosimetric predictors of radiation-induced toxicity to the immune system.
Results: An association between severe RIL and inferior survival has been described in multiple solid
tumors, including glioma, lung cancer, and pancreatic cancer. RIL risk is correlated with field size,
dose per fraction, and fraction number. SBRT and proton therapy techniques are associated with lower
RIL risk.
Conclusions: The immune system should be considered an organ at risk during RT, and absolute
lymphocyte count is an important biomarker of RT-induced immunotoxicity. Radiation dose and
technique affect the risk and severity of RIL. Further research is needed to accurately characterize
RT-induced immunotoxicity and develop strategies to prevent or mitigate this clinically significant
side effect.
 2018 The Author. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
Recent advances in immunotherapy have demonstrated
the importance of the immune system in cancer control.
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therapy (RT), which causes both acute and chronic
lymphopenia. Because lymphocytes are one of the
primary effector cells in the native immune response to
cancer, and the action of the most efficacious immuno-
therapy agents (eg, checkpoint inhibitors) is mediated by
lymphocytes, a logical mechanism links the depletion of
these critical immune cells with poorer outcomes and a
lower likelihood of response to immunotherapy.
The importance of the lymphocyte compartment in
tumor-specific immune responses is illustrated by animalcan Society for Radiation Oncology. This is an open access article under
).
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mice, T-cell deficient mice are unable to mount abscopal
responses to a combination of RT and Flt-3 ligand
enhancement.2 Clinical reports of the abscopal effect also
implicate tumor-antigen-specific cluster of differentiation
(CD) 4 lymphocytes as a key mediator of the anticancer
immune response, and have suggested that B lymphocytes
may also play a role in the generation of humoral immune
response to malignancies.3 Therefore, lymphopenia can
be intuitively proposed to diminish an individual’s ability
to mount a tumor-specific immune response.
Multiple recent studies have identified radiation-
induced lymphopenia (RIL) as a negative prognostic
factor in several treatment-refractory solid tumors,
including high-grade glioma,4e7 head and neck cancer,8
non-small9,10 and small cell lung cancer,11 esophageal
cancer,12 resected13 and unresectable14 pancreatic cancer,
and cervical cancer.15 As summarized in Table 1, the risk
and severity of RIL appears to be independent of
steroid use or concurrent chemotherapy, because this
toxicity occurs in 40% to 70% of patients treated with
fractionated RT, regardless whether corticosteroid drugs
or lymphotoxic chemotherapy agents are administered
concurrently with RT. Early clinical data also suggest
strongly that absolute lymphocyte count (ALC) is aTable 1 Radiation-induced immunosuppression as a prognostic fa
Author Primary site Concurrent therapy
Grossman (2011)7 Glioma (high
grade)
Temozolomide/
dexamethasone
Mendez (2016)5 Glioblastoma Temozolomide/
dexamethasone
Rudra (2018)4 Glioblastoma Temozolomide/
dexamethasone
Liu (2017)8 Nasopharynx Cisplatin
Davuluri (2016)12 Esophagus 5-FU (80%)
Taxane (62%)
Cisplatin (44%)
Campian (2013)9 NSCLC Carboplatin plus taxol (95%)
or gemcitabine (5%)
Tang (2014)10 NSCLC Unspecified; 81% received
chemotherapy
Cho (2016)11 SCLC Cisplatin/etoposide
Balmanoukian
(2012)13
Pancreas 5-FU (76%)
Gemcitabine (22%)
Wild (2013)14 Pancreas 5-FU (59%)
Gemcitabine (41%)
Chadha (2017)16 Pancreas Capecitabine (85%)
Gemcitabine (13%)
Cho (2016)15 Cervix uteri Cisplatin
Abbreviations: 5-FUZ 5-fluorouracil; ALCZ absolute lymphocyte count; C
lung cancer; RT Z radiation therapy; SCLC Z small cell lung cancer.
* In lymphopenic versus nonlymphopenic patients.
y 50% increase in risk of death for each 1000 cells/mL decrement in ALbiomarker of response to checkpoint blockade. Higher
lymphocyte counts are associated with a higher response
rate and more durable treatment response in patients
treated with checkpoint inhibitors.17
RIL is likely caused by direct toxicity to circulating
lymphocytes as they pass through the irradiated field,
which suggests that circulating lymphocytes should be
considered an organ at risk (OAR) during RT. The
immunosuppressive effects of total body radiation that
cause fatal bone marrow failure at even moderate doses
are well described,18 but those of focal fractionated
radiation have not been as thoroughly studied, despite
being of considerable clinical importance. As first
observed in the early 20th century, when an area of tissue
is irradiated, all circulating immune cells within the target
and penumbra regions are also exposed to potentially
lymphotoxic radiation doses.
A review article published in 1916 on the progress in
the clinical application of RT noted not only that
“the cells of the lymphoid tissue.readily succumb to the
action of the rays,” but also that “.every time we
roentgenize any given area, we thereby also radiate the
entire volume of blood” flowing through the targeted area
while the beam is on.19 Because lymphocytes are among
the most radiosensitive cell types, the effects of irradiatingctor for survival in patients with solid tumors
N Immunosuppression
measure
HR for death*
(95% CI; P-value)
96 ALC <500
2 months post-RT
1.8 (1.05-2.64; .03)
76 ALC <500
2 months post-RT
2.8 (1.30-5.86; .008)
210 ALC <500 at any time
point post-RT
1.8 (1.20-2.80; .005)
413 Post-RT ALC nadir <390 1.8 (1.12-2.78; .015)
504 Post-RT ALC nadir <500 1.6 (1.05-2.37; .027)
47 ALC <500
2 months post-RT
1.7 (0.8-3.6; .17)
711 Post-RT ALC nadir 0.59y (0.37-0.95; .03)
73 Post-RT ALC nadir <297 2.7 (1.06-6.75; .038)
2.6 (1.19-5.74; .016)
53 ALC <500
2 months post-RT
2.9 (1.53-5.41; .001)
101 ALC <500
2 months post-RT
2.2 (1.17-4.12; .01)
177 Post-RT ALC nadir <200 1.7 (1.11-2.48; .01)
152 Post-RT ALC nadir <200 1.7
IZ confidence interval; HRZ hazard ratio; NSCLCZ non-small cell
C.
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importance. The linear shape of the lymphocyte cell
survival curve after irradiation shows that exposure to
even very low doses of radiation can cause lymphocyte
cell death, because these cells lack the DNA repair
capacity that is associated with the linear-quadratic
kinetics of classic radiation survival curves in less
radiation-sensitive cell types.18,20
This review provides a brief overview of existing
evidence implicating the direct irradiation of circulating
immune cells as the proximate cause of RIL, reviews
contemporary studies on dosimetric parameters that have
been found to be correlated with the risk and severity of
radiation-induced lymphopenia, and suggests a theoretical
framework to conceptualize the immune system as an
OAR during radiation therapy. Of note, although
radiation-induced immunosuppression is comprised of a
wide spectrum of acute and chronic changes in
lymphocyte subpopulations, cytokine expression patterns,
and functional immune deficits (Table 2), its primary
clinical manifestation is absolute lymphopenia. ALC is a
clinically useful biomarker for several reasons,
including its availability at the clinic and its strong
correlation with survival in patients who receive RT, but
additional research is needed to precisely and fully
characterize the clinical syndrome of radiation-induced
immunosuppression and identify additional immuno-
logic biomarkers for response in patients who receive RT.Historical perspective
The extreme radiation sensitivity of lymphocytes was
noted by the earliest radiation therapists, who also
identified the likely mechanism of radiation-induced
lymphopenia: The irradiation of circulating immune
cells as they pass through the treated area.19 Later,
investigators described the development of radiation-
induced lymphopenia as well as functional immune
deficits in patients with breast cancer,35 pelvic tumors,36
Hodgkin’s lymphoma,37 and other malignancies. The
underlying pathophysiology of this phenomenon was
revealed by a series of experiments that clearly
demonstrated that irradiation of the circulating blood
alone caused significant and durable lymphopenia.
For example, in 1962, Cronkite et al. reported a 60%
drop in the peripheral ALC after extracorporeal irradiation
of the circulating blood in calves.38 Subsequent studies
demonstrated immunosuppression that was sufficient to
permit skin allograft acceptance in calves after
extracorporeal blood irradiation alone.39 In the late 1970s,
attempts were made to translate these findings into
humans. Weeke et al. reported on the utilization of
extracorporeal blood irradiation for immunosuppression
in renal allograft recipients.40 Patients’ circulating blood
was irradiated by passing the blood under a cesium sourceembedded within a shielded dialysis unit during
hemodialysis sessions. The shielding ensured that the
patients themselves were not exposed to direct radiation
from the cesium source. The degree of lymphopenia was
directly proportional to the source strength and number of
passes through the dialysis unit, which roughly
corresponded to the dose per fraction and number of
fractions in external beam treatment, respectively.
Additional evidence that implicated the circulating
lymphocyte compartment as the main target organ for
radiation-induced immune toxicity can be found in studies
on the immunosuppressive effects of cranial radiation.
Because the brain and skull contain little bone marrow or
lymphoid tissue, the immunosuppressive effects of whole
brain RT are probably due almost entirely to direct
toxicity and circulating lymphocytes as they flow through
the radiation field. This phenomenon was demonstrated
conclusively in a cohort of pediatric patients who were
treated with prophylactic cranial radiation for acute
lymphocytic leukemia.41 In that study, the total
whole-brain radiation dose was held constant at 2400 to
2500 rads (24-25 Gy), but the number of fractions was left
to the discretion of the treating physicians. Posttreatment
ALC was inversely proportional to the number of
fractions given, with each additional RT fraction resulting
in an additional 5% to 6% reduction in the ALC at 3
months after the end of treatment.
Focal brain radiation also causes lymphopenia, as
initially reported by Hughes et al. in a series on 76
patients with high-grade glioma who were treated with
radiation and steroidal medications. In this cohort, 24% of
patients were found to have CD4 counts <200 cells/mL by
the end of RT.42
Summary of contemporary data: Field size
and fractionation effects
On the basis of these historical observations, Yovino
et al. postulated a basic method for the calculation of
radiation dose received by circulating blood during a
course of external beam RT.43 This approach predicted
that the circulating blood dose would depend on the
fraction number, field size, and dose per fraction. The
model was highly simplified and required several
assumptions (which likely do not fully reflect physio-
logic conditions), including the following: 1) The target
volume was spherical; 2) lymphocytes were homoge-
neously distributed throughout the target, flowed at
uniform speed, and were equally radiation sensitive;
3) blood was the only structure within the target that
contained circulating immune cells (ie, did not account
for primary or secondary lymphoid structures); 4) there
was no recirculation through the field while the beam
was on; and 5) no lymphocyte repopulation occurred
during treatment.
Table 2 Summary of RT effects on circulating lymphocyte subtypes
Author/year N Site Technique Markers/Time points Findings
Maehata (2013)21 62 Lung SBRT CD3, CD4, CD8, CD19, CD56,
NKA
Baseline & weekly for 1st 4
weeks post RT
All subtypes down at 1 week post
SBRT; CD3, CD4, CD19 only
still down at 4 weeks
Rutkowski (2017)22 89 Lung SBRT T-bet, GATA-3, ROR-yT,
FoxP3, CD4, CD8
Baseline and 2 weeks, 3
months post-RT
Decreased CD4:CD8 ratio at 2
weeks persisted at 3 months;
reported % distribution only,
not absolute numbers
Nakayama (1995)23 15 Lung Conventional CD3, CD4, CD8, CD45RA,
CD56, CD20, CD11bþ
Baseline and 2 weeks after RT
Decrease in all subsets except
CD20, CD11bþ; did not report
CD4:CD8 ratio
Crocenzi (2016)24 20 Pancreas Hypo- versus
conventional
fractionation
CD3, CD4, CD8, CD45, CD27,
CD28, CD25, CD127
Baseline, 50, 100, 150, 200
days post day 1 of RT
Hypofractionated RT spared all
studied subsets; conventional
RT associated with decreased
naïve:memory cell ratio
whereas hypofractionated was
not
Tabi (2010)25 12 Prostate Hypo-fractionation CD4, CD8, CD45RA, CD27
Baseline, Day 20 RT, 4 weeks
post-RT
Decreased naïve T-cell
populations
Yang (2016)26 19 Prostate Carbon ion CD4:CD8 ratio
Baseline, after 10 fractions, last
day of RT, 1 month post-RT
Higher post-RT CD4:CD8 ratio
associated with higher
complete and partial response
rates
Van Meir (2016)27 30 Cervix uteri EBRT þ platinum CD3, CD19, MDSC, PD-1,
functional
Baseline, daily during week 1,
after 15 fx, 3, 6, 9 weeks post
RT
Increase in relative proportion of
MDSCs, decreased reactivity
to immune stimuli, increased
PD-1 expression
Santin (2002)28 15 Cervix uteri EBRT/brachy
þ/- cisplatin
CD4:CD8 ratio, NK cells
Baseline, week 5 of RT, 1
month post-RT
CD4:CD8 ratio higher in un-
transfused patients; NK cell
activity suppressed post-RT in
both groups; RT þ transfusion
/ anergy
Ellsworth (2014)29 12 Glioma EBRT þ TMZ CD3, CD4, CD8, CD45RA,
CD19, CD56, CD25, FoxP3
Baseline, 4 and 12 weeks post-
RT
Nonsignificant decline in
naïve:memory cell ratio;
significant decline in
CD4:CD8 ratio; relative
sparing of CD8 and Tregs
compared with CD4 and B
cells
Fadul (2011)30 25 Glioma EBRT þ TMZ CD3, CD4, CD8, Cd19,
CD45RO, CD56, CCR7,
CD25, CD45RA, CD14,
CCR4, FoxP3, TEMRA
Baseline, 4 weeks post-RT
Decreased CD3, CD4, CD56
populations; increased % of
Tregs; decreased TEMRA
cells; no change in
naïve:memory ratios
Campian (2017)31 20 Glioma EBRT þ TMZ CD3, CD4, CD8, CD19, NK,
CD45RA, CCR7, CD25
Baseline, end RT and 1, 3, 5, 7
months post-RT
Decrease in all subsets including
Tregs and CD8 cells.
Nonsignificant decrease in
CD4:CD8 ratio.
Parikh (2014)32 22 Oropharynx
(HPVþ)
EBRT þ platinum CD3, CD4, CD8, Treg, MDSC,
PD-1; functional assays
Baseline and 3 weeks, 3, 6, and
12 months post-RT
Decrease in all T-cell subsets
through 1-year post-RT;
increased PD-1 expression on
CD4 T cells; decreased
HPVE6/7 T cell specific
responses in patients who
(continued on next page)
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Table 2 (continued )
Author/year N Site Technique Markers/Time points Findings
initially exhibited such
responses; increased MDSC
populations
Tang (2017)33 35 Metastases SBRT þ
ipilimumab
CD4 (regulatory and effector);
CD8; 4-1BB, OX40, LAG3,
ICOS, GITR, CTLA4, TIM-3,
PD-1
Increase in absolute CD8 count
and CD8:CD4 ratio associated
with clinical benefit from
combination ipilimumab/
SBRT.
Gustafson (2017)34 10 Liver tumors
(metastases/
primary)
SBRT 110 immunophenotypes
measured
CD3, CD4 decreased; CD8 stable
CD56þCD16þ mature
(cytotoxic NK) stable
CD56brCD16 NK (precursor
NK) stable
Abbreviations: brachyZ brachytherapy; CDZ cluster of differentiation; EBRTZ external beam radiation therapy; HPVZ human papillomavirus;
MDSC Z myeloid-derived suppressor cell; NK Z natural killer; PD-1 Z programmed cell death protein 1; RT Z radiation therapy; SBRT Z
stereotactic body radiation therapy; TMZ Z temozolomide; Treg Z regulatory T cells.
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validated by prospective data that show strong
correlations between fraction number and field size with
RIL risk in patients undergoing stereotactic body RT
versus conventional radiation for pancreatic cancer.
Moreover, studies in patients with brain tumors and lung
cancer showed that the size of various isodose volumes
correlated with RIL risk. These studies are summarized in
this review.
The first report to correlate radiation field size with
severity of lymphopenia and functional immune deficits
was published in 2008 based on the study of a small
group of patients with breast cancer.44 In this series,
whole breast RT was associated with higher post-RT ALC
and natural killer cell activity compared with
comprehensive nodal irradiation fields. However, in the
absence of detailed volumetric data, the generalizability
of this finding is limited.
More recent papers have provided detailed analyses of
dosimetric parameters as predictors of lymphopenia risk.
The highest-quality data have come from studies on brain
tumors, lung cancer, and esophageal carcinoma. Tang
et al. reported on the association between field size and
acute radiation-induced lymphopenia in a group of 711
patients with non-small cell lung cancer.10 Gross tumor
volume was significantly correlated with lymphocyte
nadir, and the volume of the lung that received 5 Gy was
the only significant dosimetric predictor of postradiation
lymphocyte nadir. The authors reported on a stepwise
analysis of multiple lung volume parameters from V5
through V70 in 5-Gy increments and showed that the
strength of the correlation between lymphocyte nadir and
irradiated lung volume decreased with increasing isodose
levels. This finding highlights the extreme radiation
sensitivity of lymphocytes, because the cumulative V5
over a 6-week course of RT represents an estimated dailydose of only 0.16 Gy (assuming 30 fractions are
delivered).
In patients with high-grade glioma, Huang et al.
performed a similar stepwise analysis of dosimetric
predictors of postradiation lymphopenia.6 In this cohort of
patients, moderate isodose volumes were found to have
the strongest correlation with the risk of severe
radiation-induced lymphopenia, with a brain V25 of 65%
in patients with grade 3 lymphopenia compared with
56% in those with grade 0 to 2 lymphopenia (PZ .009).
Brain V25 was also the sole predictive dosimetric factor
for severe posttreatment lymphopenia on multivariate
analysis.
Further proof of the effects of field size on
lymphopenia risk was provided by a study of 210
patients with glioblastoma who were treated with
conventional (T1 þ T2 magnetic resonance imaging
abnormalities þ 1.5-2.5 cm margin) versus limited-
margin fields (T1 abnormality þ 1.8-2 cm margin).4
Limited-margin radiation was associated with a
significant reduction in the planning target volume (PTV)
size as well as the brain V25 and, importantly, with a
significantly higher median postradiation ALC (1100 vs
900 cells/mL in limited- vs conventional-margin group).
In addition, patients treated with limited-margin RT had a
lower absolute risk of grade 3 radiation-induced
lymphopenia (16% vs 34%), although this difference
was not statistically significant. Grade 3 lymphopenia at
any time point after radiation was independently
associated with worse progression-free and overall
survival. Although brain V25 was predictive of acute
severe lymphopenia risk, the authors did not include V25
as a prognostic factor in the survival analyses.
The unique dosimetric properties of proton beam
radiation (PBT) include decreased integral dose as well as
large reductions in both entry and exit doses.45 Therefore,
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effective field size and decrease the dose to the circulating
immune cells, thereby reducing the risk and severity of
radiation-induced lymphopenia. Shiraishi et al. reported
on a propensity-matched analysis of lymphopenia risk in a
large series of patient with esophageal cancer who were
treated with either PBT or photon radiation (136 patients
in each arm).46 The risk of grade 4 lymphopenia was
correlated with the log of PTV size in both PBT and
photon patients. The use of PBT resulted in a 71%
decrease in the risk of grade 4 lymphopenia, adjusted for
the effects of age and PTV size.
Stereotactic body RT techniques use both extreme
hypofractionation (5 fractions) and highly conformal
target volumes to deliver an ablative dose of RT. Two
recent studies in pancreatic cancer have demonstrated that
hypofractionated RT can considerably reduce the risk and
severity of radiation-induced lymphopenia. Wild et al.
measured post-RT lymphocyte counts in 133 patients with
pancreatic cancer treated either with stereotactic
body RT (6.6 Gy in 5 fractions) or conventionally
fractionated RT (30-54 Gy in 10-30 fractions), and noted
both significantly higher median post-treatment ALCs
(690 vs 358 cells/mL, P <.001) and a lower risk of grade
3 lymphopenia (14 vs 45%; PZ .007) in the stereotactic
body RT group.47
Similarly, Crocenzi et al. showed that, compared
with conventional radiation, hypofractionated RT was
associated with significantly higher post-treatment ALC
as well as higher populations of major lymphocyte
subpopulations (including CD4, CD8, CD20, and CD56
cells) throughout nearly 1 year of follow-up after RT for
pancreatic cancer.24
Conceptual approaches to immune organ-at-
risk dosimetry
A robust method to quantify the dose to the immune
OAR is essential for the development of effective strate-
gies to prevent or mitigate the risk of treatment-induced
lymphopenia in patients who require RT. However,
translating the lymphocyte OAR concept for application
in the radiation oncology clinic presents unique theoret-
ical and practical challenges because circulating immune
cells differ structurally from typical anatomic OARs
(eg, kidney or spinal cord) in several key aspects. First,
immune cells are not uniformly distributed throughout the
body, and cannot be defined by a single anatomic
structure or region. In addition, because lymphocytes are
in the bloodstream, they are constantly moving through a
radiation dose gradient while traversing the irradiated
field. Furthermore, circulating immune cells traffic among
lymphoid organs and the bloodstream are likely
replenished to some extent during treatment, and not all
are equally radiation sensitive.48Initial attempts to address the problem of calculating
the radiation dose to the circulating immune cells during
therapy considered only the dose received by the
lymphocytes carried within the bloodstream itself.43 Such
models may be sufficient for the calculation of immune
OAR dose in anatomic sites (such as the brain) that lack
high concentrations of primary or secondary lymphoid
tissues. However, in other body sites and particularly the
thorax and abdomen, lymphocyte density within the
radiation field varies on the basis of factors other than
blood flow rate and volume, and most importantly the
distribution of major lymphoid structures (lymphatic
vessels and lymph nodes as well as spleen, thymus, and
bone marrow) within the treated field.49 Therefore, an
updated method that incorporates estimates of
lymphocyte density distribution is required for the most
accurate calculation of dose to the immune OAR. The role
of lymphocyte-dense organs as major contributors to
lymphopenia risk is illustrated by 2 recent studies that
implicate spleen dose as a risk factor for RIL in patients
receiving upper abdominal RT.
Chadha et al. reported that, among 177 patients who
underwent conventionally fractionated RT for pancreatic
cancer, the mean spleen dose was highly correlated with
the risk of grade 3 lymphopenia.16 Of note, low-to-
moderate spleen doses (V5 through V20) were more
strongly correlated with lymphopenia risk than high
doses, and the median cumulative spleen dose of patients
with grade 3 lymphopenia was only 9.8 Gy (0.33 Gy/
day for a 30-fraction course), which again illustrates the
clinical significance of low-dose volumes in the induction
of radiation-induced lymphopenia.
Liu et al. also found that low-dose splenic irradiation
was correlated with lymphopenia risk, and reported that
mean spleen dose and splenic V5 were predictive of the
radiation-induced lymphopenia risk in patients with liver
cancer.50 In this series, the mean spleen dose that
predicted severe lymphopenia was also quite low, and
patients with a mean spleen dose >2.27 Gy had an
approximately 14-fold increase in the risk of severe
lymphopenia.
Conceptualizing the dose to the immune OAR in terms
of effective field size may assist in resolving some of
these difficulties. For the purposes of calculating dose to
the lymphocyte OAR, effective field size is expected to be
directly proportional to lymphocyte density within the
irradiated field, and to the amount of blood passing
through the irradiated area, which itself is related to
beam-on time (both for individual fractions and total
radiation treatment course), target volume, integral dose,
and penumbra size. In practical terms, organs that contain
very high concentrations of circulating lymphocytes, such
as the spleen and thymus, and organs with high blood
flow rates (eg, brain, liver, and kidney), would be
expected to increase effective field size with respect to
lymphopenia risk. Further investigations are needed to
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OAR dose.
Also, there are significant gaps in our knowledge with
regard to the immune system’s response to acute and
chronic radiation-induced lymphopenia. For example, the
kinetics of lymphocyte repopulation after acute radiation-
induced lymphodepletion are not well characterized but
are of potential importance when attempting to analyze
dosimetric predictors of severe lymphopenia. Anatomic
inhomogeneities in the distribution of lymphocyte sub-
types, which vary in radiation sensitivity, may also affect
the accuracy of immune OAR dose calculations.
Conclusions
Radiation-induced lymphopenia has been tied to infe-
rior survival outcomes in a wide variety of treatment-
refractory solid tumors. The risk of this common and
clinically significant toxicity appears to be directly pro-
portional to the radiation dose received by circulating
immune cells during treatment. Although the task of
developing robust methods of calculating the immune
OAR dose during RT presents considerable theoretical
and technical challenges, improving our understanding of
immune OAR dosimetry is crucial to identify effective
strategies to prevent or mitigating immunosuppression in
patients who require RT for cancer. Further research is
needed to definitively determine whether correcting or
preventing RIL improves survival in solid tumor patients.
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